Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma

Lancet

Volumn 353, Issue 9147, 1999, Pages 117-118

  Maddison, Paul ^a   Newsom Davis, John ^b   Mills, Kerry R ^b   Souhami, Robert L ^b  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; IMMUNOGLOBULIN G ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ARTICLE; AUTONOMIC DYSFUNCTION; CANCER INHIBITION; CHEMOTHERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; EATON LAMBERT SYNDROME; HUMAN; LUNG SMALL CELL CANCER; MUSCLE WEAKNESS; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; PROGNOSIS; RADIOTHERAPY; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033537356     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)76153-5     Document Type: Article

References (5)

1. 1 Elrington GM, Murray NMF, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer: a prospective survey of 150 patients. J Neurol Neurosurg Psych 1991; 54: 764-67.
2. 2 Newsom-Davis J. Neuromyotonia and the Lambert-Eaton myasthenic syndrome. In: Latov N, Wokke JHJ, Kelly JJ, eds. Immunology and infectious diseases of the peripheral nerves. Cambridge: Cambridge University Press, 1998.
3. 2+ flux in a human small cell carcinoma line. Nature 1985; 317: 737-39.
4. 4 Morris CS, Esiri MM, Marx A, Newsom-Davis J. Immunocytochemical characteristics of small cell lung carcinoma associated with the Lambert-Eaton myasthenic syndrome. Am J Pathol 1992; 140: 839-45.
5. 5 Brigham BA, Bunn PA Jr, Minna JD, Cohen MH, Ihde DC, Shackney SE. Growth rates of small cell bronchogenic carcinomas. Cancer 1978; 42: 2880-86.